Prevalence of Comorbidities and Their Impact on One-year Outcomes in Iranian Patients Hospitalized with ST-segment Elevation Myocardial Infarction
نویسندگان
1 Behavioral Disease Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
2 Behavioral Disease Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
3 Behavioral Disease Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
4 Behavioral Disease Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
5 Behavioral Disease Research Center, Kermanshah University of Medical Sciences, Kermanshah, Iran.
doi
10.22038/jctm.2024.80318.1462چکیده
Introduction: Introduction: While it is well-known that comorbidities like hypertension are associated with an increased risk for cardiovascular diseases (CVDs), the risk for death and subsequent CV complications has not been adequately addressed. Therefore, this study was aimed to examine the association between comorbidities and one-year outcomes in patients with STEMI.Methods: This hospital-based study was a part of the Kermanshah STEMI Registry. After applying inclusion criteria, a total of 2,443 patients were assessed. The data were collected using a standardized case report developed by the European Observational Registry Program (EORP). The outcomes including vital status and major adverse cardiovascular events (MACE) were assessed. We assessed the independent predictors of death and MACE using multivariable logistic regression models.Results: At first-year follow-up, out of the 2443 patients, 268 (11.06) patients died and 403 (19.0) patients experienced the MACE. On multivariate analysis, patients with hypertension (OR 1.69; 95% CI 1.19-2.38) and diabetes (OR 1.61; 95% CI 1.10-2.34) had a higher risk for death. Patients with hyperlipidemia were at the lowest risk of death (OR 0.63; 95% CI 0.41-0.97).Conclusion: Diabetes mellitus and hypertension increased the risk of death, however, hyperlipidemia decreased the risk of death. The clinical implications highlight the need for tailoring intervention in all aspects of secondary prevention of CVD especially in patients suffering from comorbidities, managing the common comorbidities, and monitoring diabetics and hypertensive patients.